{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-23-000047","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.942718+00:00","generated_at":"2026-06-15T11:40:57.008354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exelixis Q1 revenue up 15% to $408.8M, but GAAP EPS falls to $0.12 on higher R&D spend","bullets":["Total revenues $408.8M (+15% YoY); Cabozantinib franchise net product revenues $363.4M (+17% YoY).","GAAP net income $40.0M ($0.12 diluted EPS) vs $68.6M ($0.21) YoY; non-GAAP diluted EPS $0.16 vs $0.26.","R&D expense rose to $234.2M from $156.7M YoY, driven by license costs and pipeline manufacturing.","Announced $550M share repurchase program to be executed by end of 2023; reaffirms long-term confidence.","Pipeline advances: STELLAR-303 and -304 Phase 3 trials for zanzalintinib, XB002 Phase 1 dose escalation ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-23-000047","json":"https://secwatch.observer/filing/0000939767-23-000047.json","markdown":"https://secwatch.observer/filing/0000939767-23-000047.md","text":"https://secwatch.observer/filing/0000939767-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000047/0000939767-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000047/exel-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:40:57.008354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ca2d9773f02243398ec65744433eb507d3e4933","claim":"EXELIXIS, INC. reported First Quarter 2023 results: revenue $408.8 million, EPS GAAP Diluted EPS of $0.12.","evidence_excerpt":"Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast Today at 5:00 PM Eastern Time -","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000047/0000939767-23-000047-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Revenue","value":"$408.8 million"},{"label":"EPS","value":"GAAP Diluted EPS of $0.12"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}